Zymeworks (ZYME) Reiterated at Market Outperform by Citizens as Theravance Biopharma Acquisition Closed
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $32.00 price target on Zymeworks (NASDAQ: ZYME).The analyst commented, "We ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)